16th International AIDS Conference Toronto, Canada - August 13 - 18, 2006

TRANSMISSION OF HIV DRUG RESISTANCE IN EUROPE

Int Conf AIDS. 2006 Aug 13-18;16 Abstract No. TuAb0101

A.M. Wensing¹, J. Vercauteren², D.A. Vijver¹, J. Albert³, G. Poggensee⁴, J.-C. Schmit⁵, D. Struck⁵, A.M. Vandamme², B. Åsjö⁶, C. Balotta⁷, R. Camacho⁸, S. Coughlan⁹, Z. Grossman¹⁰, A. Horban¹¹, C. Kücherer¹², C. Nielsen¹³, D. Paraskevis¹⁴, E. Puchhammer-Stöckl¹⁵, C. Riva⁷, L. Ruiz¹⁶, M. Salminen¹⁷, R. Schuurman¹, A. Sonnerborg¹⁸, M. Stanojevic¹⁹, C.A. Boucher¹, on behalf of the SPREAD-programme
¹ University Medical Center Utrecht, Eijkman Winkler Center, Dept of Virology, Utrecht, Netherlands, ² Katholieke Universiteit Leuven, Rega Institute, Leuven, Belgium, ³ Swedish Institute for Infectious Disease Control, Dept of Clinical Virology, Solna, Sweden, ⁴ Robert Koch Institute, Dept. of Infectious Disease Epidemiology, Berlin, Germany, 5 Centre Hospitalier de Luxembourg, Retrovirology Laboratory, Luxembourg, Luxembourg, ⁶ University of Bergen, Center for Research in Virology, Oslo, Norway, ⁷ University of Milan, Institute of Infectious and Tropical Diseases, Milan, Italy, ⁸ Hospital Egas Moniz, Virology Laboratory, Lisbon, Portugal, ⁹ University College Dublin, National Virus Reference Laboratory, Dublin, Ireland, ¹⁰ Sheba Medical Center, National HIV Reference Laboratory, Tel-Hashomer, Israel, ¹¹ Hospital for Infectious Diseases, AIDS Diagnosis and Therapy Center, Warsaw, Poland, ¹² Robert Koch Institute, Dept. of Virology, Berlin, Germany, ¹³ Statens Serum Institute, Retrovirus Laboratory, Copenhagen, Denmark, ¹⁴ Athens University Medical School, National Retrovirus Reference Center, Athens, Greece, ¹⁵ University of Vienna, Institute of Virology, Vienna, Austria, ¹⁶ IRSICAIXA Foundation, Retrovirology Laboratory, Badalona, Spain, ¹⁷ National Publich Health Institute, HIV laboratory and Dept of infectious disease epidemiology, Helsinki, Finland, ¹⁸ Karolinska University Hospital, Division of Infectious Diseases Department of Medicine, Stockholm, Sweden, ¹⁹ University of Belgrade School of Medicine, Ministery of Health, Institute of Microbiology and Immunology, Belgrade, Serbia and Montenegro

BACKGROUND: In Europe an official European Commission supported programme monitors prospectively the prevalence of baseline HIV drug resistance and the risk factors involved in the spread of resistant HIV in 17 countries. Funding European Comission (QLK2-CT-2001-01344).

METHODS & POPULATION CHARACTERISTICS: Newly diagnosed individuals were recruited prospectively and clinical, demographic and behavioral data were collected. In 2002/2003 a total of 1083 newly diagnosed individuals were included, source of infection was: homo/bisexual (44%), heterosexual contact (42%) or iv-drug use (9%). 34% were from outside Western-Europe. 74% were asymptomatic (CDC class A). 22% had laboratory evidence of recent seroconversion (<1 year). Over 13 subtypes/CRFs were identified, predominantly B 66%, A 9%, C 9%, G 4% and CRF02_AG 4%.

RESULTS: 9.1% (96/1050, CI95% 7.5 – 11.1%) of individuals harbored viruses with drug resistance mutations (IAS-list). Prevalence was higher in seroconverters than in patients with undefined duration of infection (10.6% vs 8.7, OR = 1.2 (0.7 – 2.2; p=0.37). The prevalence of NRTI mutations was 5.4%, 1 out of 3 strains harbored more than one NRTI mutation. Most frequently observed were (n): 215Y/F/revertants (37), 41L (13), 219E/Q (10). The prevalence of PI mutations was 3.0%, most frequent observed were: 46I/L (15 ), 90M (13), 82I/F/T/S (8), The frequency of NNRTI mutations was 2.6%, mostly 103N (11) and 108I (8). Less than 1% was infected with a dual class resistant strain. Using an extensive list of risk factors no significant correlations were observed, except for individuals infected in a high prevalence country or infected with a non-B subtype virus, who had a significant lower risk of being infected with a strain harboring drug resistance mutations (5.2% vs 10.0, OR = 0.49 (0.24 – 0.99; p=0.046)) and (6.3 vs 10.4, OR= 0.57 (0.35 – 0.95; p=0.03)).

CONCLUSIONS: The SPREAD-programme provides the first representative data on transmission of HIV drug-resistance across Europe. The prevalence of 9% baseline resistance in prospectively identified newly diagnosed patients warrants continuous surveillance.

Download PDF of this abstract.

2006-08-13
TuAb0101

Copyright © 2006 - International AIDS Society (IAS). All information and content relating to the abstracts from the 16th International AIDS Conference, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is a 501c(3) not-for-profit organization made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, GlaxoSmithKline, the National Library of Medicine, Roche / Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.